Annual report pursuant to Section 13 and 15(d)

Revenues from Contracts and Significant Customers (Tables)

v3.23.1
Revenues from Contracts and Significant Customers (Tables)
12 Months Ended
Dec. 31, 2022
Revenues from Contracts and Significant Customers  
Schedule of disaggregation of total revenues

Year Ended December 31, 

    

2022

    

2021

Revenue

Qbrexza®

$

26,715

$

17,056

Accutane®

18,373

10,053

Amzeeq®

7,242

Targadox®

7,972

22,378

Ximino®

4,957

8,247

Zilxi®

2,273

Exelderm®

3,463

5,363

Other branded revenue

37

Collaboration revenue

1,882

5,389

Revenue – related party

 

192

 

268

Other revenue1

2,674

 

Net revenue

$

75,743

$

68,791

Note 1:

Other revenue for the year ended December 31, 2022 included a net $2.5 million milestone payment from Maruho Co., Ltd, upon receipt of marketing and manufacturing approval for Rapifort® Wipes 2.5% (Qbrexza®), as well as $0.2 million in royalties from Maruho on sales of Rapifort® Wipes 2.5% in Japan.